Nemocnice Mesice Centrum integrovane onkologicke pece z.s.
- Address
- Zamecka 1/2, 250 64 Mesice, Czechia
Nemocnice Měšice - Center for Integrated Oncological Care
Nemocnice Měšice Centrum integrované onkologické péče (Center for Integrated Oncological Care) is a specialized clinical research facility with demonstrated expertise in respiratory disease therapeutics. Despite its oncological designation, the center has established a strong research portfolio in advanced pulmonary medicine, focusing on chronic respiratory conditions and novel pharmacological interventions.
- Chronic Obstructive Pulmonary Disease (COPD) with focus on exacerbation prevention and triple therapy optimization
- Advanced asthma management including patients uncontrolled on ICS-containing maintenance therapy
- Novel therapeutic agents including phosphodiesterase inhibitors as add-on treatments
The center has particular expertise in evaluating CHF6001 (Tanimilast), an investigational compound, across multiple respiratory indications. Their research emphasizes exacerbation reduction in both COPD and asthma populations, with rigorous assessment of efficacy when added to existing maintenance therapies including ICS/LABA combinations and triple therapy regimens. The facility conducts long-term studies extending to 52 weeks, demonstrating capability for comprehensive safety and efficacy evaluation in complex respiratory disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Mesice Centrum integrovane onkologicke pece z.s.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tanimilast | 3 | Unknown | 2021-06-16 | 2023-11-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.